Sen. Richard Blumenthal Sells Shares of Oncology Institute, Inc. (NASDAQ:STLN)

Senator Richard Blumenthal (Democratic-Connecticut) recently sold part of their stake in Oncology Institute, Inc. (NASDAQ:STLN). In a filing disclosed on October 26th, the Senator disclosed that they had sold between $1,001 and $15,000 in Oncology Institute stock on September 23rd.

Senator Richard Blumenthal also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/22/2026.
• Sold $1,001 – $15,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/22/2026.
• Sold $15,001 – $50,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/18/2026.
• Sold $1,001 – $15,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/18/2026.

Oncology Institute Stock Down 6.3%

Shares of STLN stock opened at $6.29 on Tuesday. The company has a market cap of $621.70 million, a P/E ratio of -20.97 and a beta of 0.39. Oncology Institute, Inc. has a 12-month low of $2.32 and a 12-month high of $7.13. The company’s 50-day moving average price is $6.46.

Oncology Institute (NASDAQ:STLN) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.08) earnings per share for the quarter. The business had revenue of $161.28 million for the quarter, compared to analysts’ expectations of $152.80 million. As a group, equities research analysts predict that Oncology Institute, Inc. will post -0.21 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Lake Street Capital started coverage on shares of Oncology Institute in a research note on Monday, July 6th. They set a “buy” rating and a $10.00 price target on the stock. Weiss Ratings initiated coverage on Oncology Institute in a report on Thursday, August 6th. They set a “sell (d-)” rating on the stock. BTIG Research upped their price objective on Oncology Institute from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Thursday, July 9th. Finally, Needham & Company LLC increased their price objective on Oncology Institute from $7.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, October 14th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $9.00.

Insider Transactions at Oncology Institute

In other news, Director Brad Hively sold 298,853 shares of the business’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $6.51, for a total transaction of $1,945,533.03. Following the completion of the transaction, the director directly owned 411,976 shares in the company, valued at approximately $2,681,963.76. The trade was a 42.04% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Jorey Chernett purchased 12,000 shares of the stock in a transaction dated Friday, August 14th. The stock was bought at an average cost of $6.54 per share, with a total value of $78,480.00. Following the completion of the purchase, the insider owned 10,660,858 shares in the company, valued at $69,722,011.32. The trade was a 0.11% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Corporate insiders own 4.40% of the company’s stock.

Hedge Funds Weigh In On Oncology Institute

Hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. bought a new stake in shares of Oncology Institute during the 2nd quarter valued at $25,787,000. State Street Corp bought a new position in shares of Oncology Institute in the 2nd quarter worth $8,432,000. Renaissance Technologies LLC grew its stake in shares of Oncology Institute by 25.1% during the first quarter. Renaissance Technologies LLC now owns 902,809 shares of the company’s stock worth $2,772,000 after purchasing an additional 180,909 shares during the period. FourWorld Capital Management LLC grew its stake in shares of Oncology Institute by 30.4% during the first quarter. FourWorld Capital Management LLC now owns 499,196 shares of the company’s stock worth $1,533,000 after purchasing an additional 116,496 shares during the period. Finally, Manatuck Hill Partners LLC bought a new stake in Oncology Institute in the second quarter valued at about $2,444,000. 36.86% of the stock is owned by institutional investors.

About Senator Blumenthal

Richard Blumenthal (Democratic Party) is a member of the U.S. Senate from Connecticut. He assumed office on January 3, 2011. His current term ends on January 3, 2029. Blumenthal (Democratic Party, Working Families Party) ran for re-election to the U.S. Senate to represent Connecticut. He won in the general election on November 8, 2022. Before his election to the Senate, Blumenthal had served as the Connecticut Attorney General since 1991. He served in the Connecticut State Senate from 1987 to 1991 and in the Connecticut House of Representatives from 1984 to 1987. As of a 2014 analysis of multiple outside rankings, Blumenthal is one of the most reliable Democratic votes, meaning he can be considered a safe vote for the Democratic Party in Congress.

Oncology Institute Company Profile

The Oncology Institute is a value-based oncology care company focused on delivering comprehensive cancer treatment and related services through community-based care settings. Its model is designed to support patients throughout the cancer-care journey while coordinating treatment among oncologists, primary-care providers, specialists and other healthcare professionals.

The company provides medical oncology and hematology services, cancer screening and diagnosis, treatment planning, chemotherapy and other infusion therapies, supportive care, survivorship services and care-management programs.